Supplementary file 7 – Additional references

[S1] Baird GL, Harlow LL, Machan JT, *et al*. Cluster reduction in patients in a pilot treatment trial for psychogenic nonepileptic seizures. *Epilepsy Behav* 2017;**73**:273-279.

[S2] LaFrance WC,Jr., Baird GL, Barry JJ, *et al*. Multicenter Pilot Treatment Trial for Psychogenic Nonepileptic Seizures A Randomized Clinical Trial. *JAMA Psychiatry* 2014;**71**(9):997-1005.

[S3] Thompson N, Connelly L, Peltzer J, *et al*. Psychogenic nonepileptic seizures: a pilot study of a brief educational intervention. *Perspect Psychiatr Care* 2013;**49**(2):78-83.

[S4] Tolchin B., Baslet G., Suzuki J., *et al*. Randomized controlled trial of motivational interviewing for psychogenic nonepileptic seizures. *Epilepsia* 2019;**60**(5):986-995.

[S5] Dallocchio C, Tinazzi M, Bombieri F, *et al*. Cognitive Behavioural Therapy and Adjunctive Physical Activity for Functional Movement Disorders (Conversion Disorder): a Pilot, Single-Blinded, Randomized Study. *Psychother Psychosom* 2016;**85**(6):381-383.

[S6] Kompoliti K, Wilson B, Stebbins G, *et al*. Immediate vs. delayed treatment of psychogenic movement disorders with short term psychodynamic psychotherapy: randomized clinical trial. *Parkinsonism Relat Disord* 2014;**20**(1):60-63.

[S7] Taib S, Ory-Magne F, Brefel-Courbon C, *et al*. Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study. *Mov Disord* 2019;**34:**1210-1219.

[S8] Vizcarra J.A., LopezCastellanos J.R., Dwivedi A.K., *et al*. OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. *Parkinsonism Relat Disord* 2019;**63:**174-178.

[S9] Garcin B, Mesrati F, Hubsch C, *et al*. Impact of transcranial magnetic stimulation on functional movement disorders: cortical modulation or a behavioral effect? *Front Neurol* 2017;**8**:338.

[S10] Dreissen YEM, Dijk JM, Gelauff JM, *et al*. Botulinum neurotoxin treatment in jerky and tremulous functional movement disorders: a double-blind, randomised placebo-controlled trial with an open-label extension. *J Neurol Neurosurg Psychiatry* 2019 Epub ahead of print 20th June 2019. doi: 10.1136/jnnp-2018-320071

[S11] Jordbru AA, Smedstad LM, KlungsÃ¸yr O, *et al*. Psychogenic gait disorder: a randomized controlled trial of physical rehabilitation with one-year follow-up. *J Rehabil Med* 2014;**46**(2):181-187.

[S12] McWhirter L, Ludwig L, Carson A, *et al*. Transcranial magnetic stimulation as a treatment for functional (psychogenic) upper limb weakness. *J Psychosom Res* 2016;**89**:102-106.

[S13] Broersma M, Koops EA, Vroomen PC, *et al*. Can repetitive transcranial magnetic stimulation increase muscle strength in functional neurological paresis? A proof-of-principle study. *Eur J Neurol* 2015;**22**(5):866-873.

[S14] Nielsen G, Stone J, Buszewicz M, *et al.* Physio4FMD: protocol for a multicentre randomised controlled trial of specialist physiotherapy for functional motor disorder. *BMC Neurol* 2019;**19,** 242. doi:10.1186/s12883-019-1461-9

[S15] Nielsen G, Buszewicz M, Stevenson F, *et al*. Randomised feasibility study of physiotherapy for patients with functional motor symptoms. *J Neurol Neurosurg Psychiatr* 2017;**88**(6):484-490.

[S16] Moene FC, Spinhoven P, Hoogduin KA, *et al*. A randomised controlled clinical trial on the additional effect of hypnosis in a comprehensive treatment programme for in-patients with conversion disorder of the motor type. *Psychother Psychosom* 2002;**71**(2):66-76.

[S17] Moene FC, Spinhoven P, Hoogduin KA, *et al*. A randomized controlled clinical trial of a hypnosis-based treatment for patients with conversion disorder, motor type. *Int J Clin Exp Hypn* 2003;**51**(1):29-50.

[S18] Rampello L, Raffaele R, Nicoletti G, *et al*. Hysterical neurosis of the conversion type: therapeutic activity of neuroleptics with different hyperprolactinemic potency. *Neuropsychobiol* 1996;**33**(4):186-188.

[S19] Hubschmid M, Aybek S, Maccaferri GE, *et al*. Efficacy of brief interdisciplinary psychotherapeutic intervention for motor conversion disorder and nonepileptic attacks. *Gen Hosp Psychiatry* 2015;**37**(5):448-455.

[S20] Sharpe M, Walker J, Williams C, *et al*. Guided self-help for functional (psychogenic) symptoms: a randomized controlled efficacy trial. *Neurology* 2011;**77**(6):564-572.

[S21] Mousavi SG, Rahimi J, Afshar H. Comparison of four different treatment options in the management of acute conversion disorder. *Iranian J Psychiatry Behav Sci* 2008;**2**(1):21-25.

[S22] Pleizier M, de Haan RJ, Vermeulen M. Management of patients with functional neurological symptoms: a single-centre randomised controlled trial. *J Neurol Neurosurg Psychiatry* 2017;**88**(5):430-436.

[S23] Demartini B, Volpe R, Mattavelli G, *et al*. The neuromodulatory effect of tDCS in patients affected by functional motor symptoms: an exploratory study. *Neurol Sci* 2019;**40**(9):1821-1827.

[S24] Beecham J, Knapp M. Costing psychiatric interventions. *Measuring Mental Health Needs.* Gaskell, London, UK 2001; 200-224.

[S25] Herdman M, Gudex C, Lloyd A, *et al*. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;**20**(10):1727-1736.

[S26] Broadbent E, Petrie KJ, Main J, *et al*. The brief illness perception questionnaire. *J Psychosom Res* 2006;**60**(6):631-637.

[S27] Weinman J, Petrie KJ, Moss-Morris R, *et al*. The illness perception questionnaire: a new method for assessing the cognitive representation of illness. *Psychol Health* 1996;**11**(3):431-445.

[S28] Moss-Morris R, Weinman J, Petrie K, *et al*. The revised illness perception questionnaire (IPQ-R). *Psychol Health* 2002;**17**(1):1-16.

[S29] Carson AJ, Stone J, Hansen CH, *et al*. Somatic symptom count scores do not identify patients with symptoms unexplained by disease: a prospective cohort study of neurology outpatients. *J Neurol Neurosurg Psychiatry* 2015;**86**(3):295-301.

[S30] Demartini B., Petrochilos P., Edwards M.J., *et al*. Multidisciplinary treatment for functional neurological symptoms: A prospective study. *J Neurol* 2014;**261:** 2370-2377.

[S31] Conwill M, Oakley L, Evans K, *et al*. CBT-based group therapy intervention for nonepileptic attacks and other functional neurological symptoms: a pilot study. *Epilepsy Behav* 2014;**34**:68-72.

[S32] Demartini B, Bombieri F, Goeta D, *et al*. A physical therapy programme for functional motor symptoms: A telemedicine pilot study. *Parkinsonism Relat Disord* 2019 Epub ahead of print 3rd May 2019. doi: 10.1016/j.parkreldis.2019.05.004

[S33] Garcin B, Roze E, Mesrati F, *et al*. Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders. *J Neurol Neurosurg Psychiatry* 2013;**84**(9):1043-1046.

[S34] Nielsen G, Ricciardi L, Demartini B, *et al*. Outcomes of a 5-day physiotherapy programme for functional (psychogenic) motor disorders. *J Neurol* 2015;**262**(3):674-681.

[S35] Voon V, Lang A. Antidepressant treatment outcomes of psychogenic movement disorder. *J Clin Psychiatry* 2005;**66**(12):1529-1534.

[S36] de Barros ACS, Furlan AER, Marques LHN, *et al*. Effects of a psychotherapeutic group intervention in patients with refractory mesial temporal lobe epilepsy and comorbid psychogenic nonepileptic seizures: A nonrandomized controlled study. *Seizure* 2018;**58:**22-28.

[S37] Kuyk J, Siffels MC, Bakvis P, *et al*. Psychological treatment of patients with psychogenic non-epileptic seizures: an outcome study. *Seizure* 2008;**17**(7):595-603.

[S38] Bullock KD, Mirza N, Forte C, *et al*. Group Dialectical-Behavior Therapy Skills Training for Conversion Disorder With Seizures. *J Neuropsychiatry Clin Neurosci* 2015;**27**(3):240-243.

[S39] Goldstein LH, Deale AC, Mitchell-O'Malley SJ, *et al*. An Evaluation of Cognitive Behavioral Therapy As A Treatment for Dissociative Seizures: A Pilot Study. *Cogn Behav Neurol* 2004;**17**(1):41-49.

[S40] LaFrance WCJ, Friedman JH. Cognitive behavioral therapy for psychogenic movement disorder. *Mov Disord* 2009;**24**(12):1856-1857.

[S41] Mayor R, Howlett S, Grunewald R, *et al*. Long-term outcome of brief augmented psychodynamic interpersonal therapy for psychogenic nonepileptic seizures: Seizure control and health care utilization. *Epilepsia* 2010;**51**(7):1169-1176.

[S42] Metin SZ, Ozmen M, Metin B, *et al*. Treatment with group psychotherapy for chronic psychogenic nonepileptic seizures. *Epilepsy Behav* 2013;**28**(1):91-94.

[S43] Myers L, Vaidya-Mathur U, Lancman M. Prolonged exposure therapy for the treatment of patients diagnosed with psychogenic non-epileptic seizures (PNES) and post-traumatic stress disorder (PTSD). *Epilepsy Behav* 2017;**66**:86-92.

[S44] Pintor L, Bailles E, Matrai S, *et al*. Efficiency of venlafaxine in patients with psychogenic nonepileptic seizures and anxiety and/or depressive disorders. *J Neuropsychiatry Clin Neurosci* 2010;**22**(4):401-408.

[S45] Cope SR, Smith JG, King T, *et al*. Evaluation of a pilot innovative cognitive-behavioral therapy-based psychoeducation group treatment for functional non-epileptic attacks. *Epilepsy Behav* 2017;**70**(Pt A):238-244.

[S46] Dallocchio C, Arbasino C, Klersy C, *et al*. The effects of physical activity on psychogenic movement disorders. *Mov Disord* 2010;**25**(4):421-425.

[S47] Ferrara J, Stamey W, Strutt AM, *et al*. Transcutaneous Electrical Stimulation (TENS) for Psychogenic Movement Disorders. *J Neuropsychiatry Clin Neurosci* 2011;**23**(2):141-148.

[S48] Espay AJ, Edwards MJ, Oggioni GD, *et al*. Tremor retrainment as therapeutic strategy in psychogenic (functional) tremor. *Parkinsonism Relat Disord* 2014;**20**(6):647-650.

[S49] Reuber M, Burness C, Howlett S, *et al*. Tailored psychotherapy for patients with functional neurological symptoms: A pilot study. *J Psychosom Res* 2007;**63**(6):625-632.

[S50] Barry JJ, Wittenberg D, Bullock KD, *et al*. Group therapy for patients with psychogenic nonepileptic seizures: a pilot study. *Epilepsy Behav* 2008;**13**(4):624-629.

[S51] Aybek S, Hubschmid M, Mossinger C, *et al*. Early intervention for conversion disorder: neurologists and psychiatrists working together. *Acta Neuropsychiatr* 2013;**25**(1):52-56.

[S52] Zaroff CM, Myers L, Barr WB, *et al*. Group psychoeducation as treatment for psychological nonepileptic seizures. *Epilepsy Behav* 2004;**5**(4):587-592.

[S53] Kozlowska K., Chudleigh C., Cruz C.*, et al*. Psychogenic non-epileptic seizures in children and adolescents: Part II - explanations to families, treatment, and group outcomes. *Clin Child Psychol Psychiatry* 2018;**23**(1):160-176.

[S54] Duncan R, Anderson J, Cullen B*, et al*. Predictors of 6-month and 3-year outcomes after psychological intervention for psychogenic non epileptic seizures. *Seizure* 2016;**36**:22-26.

[S55] Ashworth M. PSYCHLOPS–a psychometric outcome measure that is finding a niche. *Couns Psychother Res* 2007;**7**(4):201-202.

[S56] Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. *Clin Rehabil* 2009;**23**(4):362-370.

[S57] Berk M, Ng F, Dodd S*, et al*. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. *J Eval Clin Pract* 2008;**14**(6):979-983.

[S58] Khan A, Khan S, Shankles E*, et al*. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. *Int Clin Psychopharmacol* 2002;**17**(6):281-285.

[S59] Hedges DW, Brown BL, Shwalb DA. A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. *Hum Psychopharmacol Clin Exp* 2009;**24**(1):35-40.

[S60] Forkmann T, Scherer A, Boecker M*, et al*. The clinical global impression scale and the influence of patient or staff perspective on outcome. *BMC Psychiatry* 2011;**11**(1):83.

[S61] Leon AC, Shear MK, Klerman GL*, et al*. A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression. *J Clin Psychopharmacol* 1993;.

[S62] Haro J, Kamath S, Ochoa S*, et al*. The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. *Acta Psychiatr Scand* 2003;**107**:16-23.

[S63] Spearing MK, Post RM, Leverich GS*, et al*. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. *Psychiatry Res* 1997;**73**(3):159-171.

[S64] Asadi-Pooya AA, Bahrami Z. Frequency of attacks in patients with psychogenic non-epileptic seizures. *Epileptic Disord* 2019;**21**(4):371-374.

[S65] Kocalevent R, Hinz A, Brähler E. Standardization of a screening instrument (PHQ-15) for somatization syndromes in the general population. *BMC Psychiatry* 2013;**13**(1):91.

[S66] van Ravesteijn H, Wittkampf K, Lucassen P*, et al*. Detecting somatoform disorders in primary care with the PHQ-15. *Ann Fam Med* 2009;**7**(3):232-238.

[S67] Han C, Pae C, Patkar AA*, et al*. Psychometric properties of the Patient Health Questionnaire–15 (PHQ–15) for measuring the somatic symptoms of psychiatric outpatients. *Psychosomatics* 2009;**50**(6):580-585.

[S68] Hyphantis T, Kroenke K, Papatheodorou E*, et al*. Validity of the Greek version of the PHQ 15-item Somatic Symptom Severity Scale in patients with chronic medical conditions and correlations with emergency department use and illness perceptions. *Compr Psychiatry* 2014;**55**(8):1950-1959.

[S69] Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. *J Psychosom Res* 2000;**48**(6):579-584.

[S70] Abiodun O. A validity study of the Hospital Anxiety and Depression Scale in general hospital units and a community sample in Nigeria. *B J Psych* 1994;**165**(5):669-672.

[S71] Aydemir Ö, Guvenir T, Kuey L, *et al*. Validity and reliability of Turkish version of hospital anxiety and depression scale. *Turk Psikiyatri Derg* 1997;**8**(4):280-287.

[S72] Bjelland I, Dahl AA, Haug TT, *et al*. The validity of the Hospital Anxiety and Depression Scale: an updated literature review. *J Psychosom Res* 2002;**52**(2):69-77.

[S73] Terkawi AS, Tsang S, AlKahtani GJ, *et al*. Development and validation of Arabic version of the Hospital Anxiety and Depression Scale. *Saudi J Anaesth* 2017;**11**(Suppl 1):S11-S18.

[S74] Wiglusz MS, Landowski J, Michalak L, *et al*. Validation of the Hospital Anxiety and Depression Scale in patients with epilepsy. *Epilepsy Behav* 2016;**58**:97-101.

[S75] Kojima M, Furukawa TA, Takahashi H, *et al*. Cross-cultural validation of the Beck Depression Inventory-II in Japan. *Psychiatry Res* 2002;**110**(3):291-299.

[S76] Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clin Psychol Rev* 1988;**8**(1):77-100.

[S77] Steer RA, Ranieri WF, Beck AT, *et al*. Further evidence for the validity of the Beck Anxiety Inventory with psychiatric outpatients. *J Anxiety Disord* 1993;**7**(3):195-205.

[S78] Wang Y, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. *Braz J Psychiatry* 2013;**35**(4):416-431.

[S79] Nuevo R, Dunn G, Dowrick C, *et al*. Cross-cultural equivalence of the Beck Depression Inventory: A five-country analysis from the ODIN study. *J Affect Disord* 2009;**114**(1-3):156-162.

[S80] Wagner AK, Gandek B, Aaronson NK, *et al*. Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA project. *J Clin Epidemiol* 1998;**51**(11):925-932.

[S81] Aaronson NK, Muller M, Cohen PD, *et al*. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. *J Clin Epidemiol* 1998;**51**(11):1055-1068.

[S82] Brazier JE, Harper R, Jones NM, *et al*. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ* 1992;**305**(6846):160-164.

[S83] Hunter RM, Baio G, Butt T, *et al*. An educational review of the statistical issues in analysing utility data for cost-utility analysis. *Pharmacoeconomics* 2015;**33**(4):355-366.

[S84] Brazier J, Usherwood T, Harper R, *et al*. Deriving a preference-based single index from the UK SF-36 Health Survey. *J Clin Epidemiol* 1998;**51**(11):1115-1128.

[S85] Choy EH, Mease PJ. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). *Rheum Dis Clin North Am* 2009;**35**(2):329-337.

[S86] Turk DC, Dworkin RH, Allen RR, *et al*. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2003;**106**(3):337-345.

[S87] Dworkin RH, Turk DC, Farrar JT, *et al*. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2005;**113**(1-2):9-19.

[S88] Grieve S, Perez RSGM, Birklein F, *et al*. Recommendations for a first Core Outcome Measurement set for complex regional PAin syndrome Clinical sTudies (COMPACT). *Pain* 2017;**158**(6):1083-1090.

[S89] Rief W, Burton C, Frostholm L, *et al*. Core Outcome Domains for Clinical Trials on Somatic Symptom Disorder, Bodily Distress Disorder, and Functional Somatic Syndromes: European Network on Somatic Symptom Disorders Recommendations. *Psychosom Med* 2017;**79**(9):1008-1015.